A previously mentioned alternative to this strategy is clearly the delivery of the LTβR ligands LTα, LTβ, or LIGHT, agonist anti-LTβR antibodies or downstream TLO-associated chemokines (CCL19, CCL21, CXCL13) via protein-based or genetic therapy in order to instigate the locoregional development of TLO in the TME leading to inhibition of tumor growth in vivo and extended overall survival (8, 9, 48, 74, 75). The gene discussed is TNFSF14; the disease is neoplasm.